The goal of PrEP is to prevent HIV infection by taking one pill every day. Recently, HPTN investigators Chris Beyrer and Linda-Gail Bekker, along with their colleagues, collaborated to write an article published in the prestigious journal The Lancet, urging the health care community to make PrEP more available:
“The science is now clear: oral pre-exposure prophylaxis (PrEP) with …Truvada significantly reduces the risk of HIV infection among individuals at high risk of HIV infection. The news that PrEP has shown consistent efficacy among those who take it as prescribed should be a cause for celebration, and galvanise action to ensure access to PrEP for those who could benefit the most. But almost 3 years since the US Food and Drug Administration approved [Truvada] for PrEP, little is being done on implementation.”
To read the full article, click here.